DYAX 13.18 Dyax Corp $DYAX Hit a 52 week high of 13.18

New Post Public Reply Private Reply Replies (0) Message Board

Nov 10, 2014 at 11:09 PM

DYAX 13.18 Dyax Corp $DYAX Hit a 52 week high of 13.18 Closing the day 11/10/14 at 13.18 +0.40 +3.13% With a day low of 12.62 and a total volume of 1,215,096.

DYAX Recent Posts: http://investorshangout.com/Dyax-DYAX-53955/

DYAX Dyax Corp Recent Headline News

Dyax Up 73.8% Since SmarTrend Uptrend Call (DYAX)
Comtex SmarTrend(R) - Mon Nov 10, 4:46PM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 6 months, Dyax has returned 73.76% as of today's recent price of $13.18.
DYAX: 13.18 (+0.40)

Why Dyax (DYAX) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:42AM CST
Dyax's stock not only has a decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well, suggesting that it could be a solid choice for investors.
DYAX: 13.18 (+0.40)

Can Dyax (DYAX) Stock Continue to Grow Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 7:49AM CST
Dyax possess a positive long term growth rate and favorable Zacks Rank
DYAX: 13.18 (+0.40)

Dyax Shares Up 62.1% Since SmarTrend's Buy Recommendation (DYAX)
Comtex SmarTrend(R) - Mon Nov 03, 10:56AM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 62.07% as of today's recent price of $12.29.
DYAX: 13.18 (+0.40)

Dyax Corp. Announces Expansion of Phase 1b Clinical Trial for DX-2930
Business Wire - Mon Nov 03, 6:30AM CST
Dyax Corp. (NASDAQ: DYAX) today announced the expansion of its ongoing Phase 1b clinical trial evaluating DX-2930 to include additional patients and dosing cohorts. Dyax is developing DX-2930, an investigational fully human monoclonal antibody inhibitor of plasma kallikrein, as a subcutaneous injection for prevention of hereditary angioedema (HAE) attacks.
DYAX: 13.18 (+0.40)

BIND Therapeutics, Inc. (BIND) Surges: Stock Rises 14.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:11AM CDT
BIND Therapeutics, Inc. (BIND) was a big mover last session, as the company saw its shares rise over 14% on the day.
BIIB: 327.87 (+7.12), AMAG: 34.91 (-0.04), BIND: 9.64 (+0.42), DYAX: 13.18 (+0.40)

Update: Biotech Dyax Exceeds Q3 Estimates With The Future Looking Bright
David Zanoni - at Seeking Alpha - Thu Oct 30, 11:15AM CDT

DYAX: 13.18 (+0.40)

Will Dyax (DYAX) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:04AM CDT
Will Dyax (DYAX) Continue to Surge Higher?
DYAX: 13.18 (+0.40)

Dyax ups earnings 87% in Q3
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 8:53AM CDT

DYAX: 13.18 (+0.40)

Dyax's (DYAX) CEO Gustav Christiansen on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Oct 28, 7:54PM CDT

DYAX: 13.18 (+0.40)

Dyax beats Street 3Q forecasts
Automated Insights - Tue Oct 28, 4:48PM CDT
BURLINGTON, Mass. (AP) _ Dyax Corp. (DYAX) on Tuesday reported a loss of $816,000 in its third quarter.
DYAX: 13.18 (+0.40)

Dyax (DYAX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Oct 28, 3:55PM CDT

DYAX: 13.18 (+0.40)

Dyax beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 3:16PM CDT

DYAX: 13.18 (+0.40)

Dyax Corp. Announces Third Quarter 2014 Financial Results
Business Wire - Tue Oct 28, 3:01PM CDT
Dyax Corp. (NASDAQ: DYAX) today announced financial results for the third quarter ended September 30, 2014. Dyax will host a webcast and conference call at 5:00 p.m. (ET) today to review financial results and provide updates regarding its key value drivers -including the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio (LFRP).
DYAX: 13.18 (+0.40)

Notable earnings after Tuesday's close
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 4:35PM CDT

EA: 41.26 (+0.32), BXP: 128.29 (+0.47), AMP: 130.16 (+1.11), MRCY: 13.75 (+0.24), BLDP: 2.79 (-0.03), ESRX: 77.99 (+0.12), AJG: 48.26 (+0.16), NANO: 14.45 (+0.15), CAP: 22.69 (-0.06), EXTR: 3.83 (+0.05), HTA: 12.50 (+0.09), AEC: 19.49 (+0.25), MCK: 201.28 (+1.96), BGFV: 12.93 (-0.02), FB: 75.00 (-0.60), ARI: 16.58 (+0.13), EXP: 87.89 (+1.37), MWA: 9.91 (+0.12), DYAX: 13.18 (+0.40), FARO: 55.64 (+0.43), NFX: 33.26 (-0.31), KONA: 23.12 (+0.36), AZPN: 38.03 (+0.44), GILD: 107.02 (+0.57), HIW: 42.88 (+0.43), PEI: 21.73 (+0.25), GFIG: 4.86 (-0.08), CHRW: 72.17 (+0.71), HURN: 70.43 (+1.15), DLR: 68.61 (+0.84), HLIT: 6.91 (-0.16), AMCC: 6.32 (-0.14), INVN: 14.95 (-0.25), BOOM: 17.54 (+0.04), CINF: 51.43 (+0.32), KIM: 24.94 (+0.15), OI: 25.88 (-0.12), GPRE: 34.28 (-0.75), EPR: 57.48 (+0.87), APC: 92.34 (-1.97), IPHI: 14.59 (-0.44), HTS: 19.05 (+0.06), MAR: 76.56 (+1.06), INAP: 8.16 (+0.01), CRAY: 34.60 (+0.68), FEIC: 84.01 (+0.13), FISV: 70.07 (+0.61), DNB: 124.28 (+1.15), AFG: 60.69 (-0.02), CEB: 74.82 (+0.99), KEYW: 10.59 (+0.35), PLT: 52.18 (+0.03), MAC: 69.55 (+1.07), CHMT: 23.36 (-0.03), AFL: 59.06 (+0.17), CBT: 46.86 (+0.01), EIX: 63.08 (+0.70), EQR: 70.46 (+1.17)

Shares of DYAX Up 41.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Oct 27, 9:38AM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 41.60% as of today's recent price of $10.74.
DYAX: 13.18 (+0.40)

Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon
PR Newswire - Mon Oct 27, 7:35AM CDT
Investor-Edge has initiated coverage on the following equities: Neurocrine Biosciences Inc. (NASDAQ: NBIX), Insmed Inc. (NASDAQ: INSM), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Dyax Corporation (NASDAQ: DYAX), and Oncothyreon Inc. (NASDAQ: ONTY). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 24, 2014, the NASDAQ Composite ended at 4,483.72, up 0.69%, the Dow Jones Industrial Average advanced 0.76%, to finish the day at 16,805.41, and the S&P 500 closed at 1,964.58, up 0.71%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 754.42, up 1.38%, with the index also advancing 5.41% in the previous three months. Register for your complimentary reports on these five stocks at:
INSM: 14.32 (+0.19), BCRX: 11.16 (+0.70), NBIX: 18.98 (+0.40), ONTY: 1.67 (+0.07), DYAX: 13.18 (+0.40)

Dyax Has Returned 31.6% Since SmarTrend Recommendation (DYAX)
Comtex SmarTrend(R) - Mon Oct 20, 9:12AM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 31.58% as of today's recent price of $9.98.
DYAX: 13.18 (+0.40)

Dyax Corp. to Host Third Quarter 2014 Earnings Call and Webcast
Business Wire - Tue Oct 14, 7:00AM CDT
Dyax Corp. (NASDAQ

YAX) will host a webcast and conference call, including an open question and answer session, Tuesday, October 28, 2014. During the call, management will discuss the Company's financial results for the third quarter 2014 as well as progress regarding its key value drivers - the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio (LFRP).
DYAX: 13.18 (+0.40)

Dyax Up 25.6% Since SmarTrend Uptrend Call (DYAX)
Comtex SmarTrend(R) - Fri Oct 10, 5:12PM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 25.64% as of today's recent price of $9.53.
DYAX: 13.18 (+0.40)

Dyax Corp. (DYAX) Stock Research Links

DYAX Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MINISFORUM Strikes with New AI Powerhouses at IFA

MINISFORUM's Bold Move in Edge AI Computing There's no doubt that 2026 is about AI making its way to the forefront, and MINISFORUM is moving full steam ahead. Introduced at the IFA in Berlin, MINISFORUM unveiled its latest input into the edge AI scene with the AMD Ryzen AI MAX+ PRO 495 driving the charge. Now, these aren't just ordinary upgrades, mind you. We're talking...

Alcatraz AI: A Silent Titan in Data Center Security

Why Alcatraz AI is the Security of Choice Forget flashy press releases and splashy marketing campaigns. Alcatraz AI, a company operating out of the hustle and bustle of Cupertino, has managed to quietly dominate a key sector without many folks being the wiser. What's their claim to fame, you ask? They're the chosen gatekeepers for over half of the hyperscale data centers...

USSM and IonicRE Partner to Enhance US Rare Earths Supply

Sometimes, it's not just about playing the game, but knowing which card to play. US Strategic Metals (USSM) and Ionic Rare Earths USA just unveiled a strategic move that’s likely to shake things up in the wild world of rare earths. As the partnership gears up to build a magnet recycling facility in Missouri, there’s chatter around creating a sustainable supply chain...

TCL's Energy Vision Unveiled at IFA 2026

TCL's Forward-Thinking Approach at IFA 2026 IFA 2026 in Berlin got a jolt when TCL Industries and TCL Technology rolled out their ambitious plans under the banner "Inspiration Habitat." By blending cutting-edge smart devices with clean energy advancements, TCL is frantically waving red flags for anyone with an eye on future living trends. The Heartbeat of Inspiration...

Courtesy Auto Group Expands with Tucson Dealerships Buy

Moving Pieces in the Automotive Puzzle Here's one for the books, folks. Automotive dealership chessboard gets another shuffle. Scott Gruwell, the big wheel behind Courtesy Automotive Group, has snatched up Watson Chevrolet and Infiniti of Tucson. Just one more notch in someone's power belt—operations now rolling under new banners as Courtesy Chevrolet and Courtesy...

Graphic Packaging Names Berardinelli as HR Executive

A New Chapter in HR Leadership at Graphic Packaging September 8 marks a turning point for Graphic Packaging Holding Company with the appointment of Tatiana Berardinelli as their new Chief Human Resources Officer. As NYSE:GPK positions itself for ambitious growth, Berardinelli stands out for her knack for managing transformations and building cultures that thrive in...

Shane Strum to Lead Memorial with Renewed Vision

Strum's Permanent Role: A New Era of Healthcare If you'd said two years ago Shane Strum would be locked in as the permanent CEO of Memorial Healthcare System, some folks would've shrugged. But here we are, with the Board of Commissioners putting their full chips on Strum, confirming his spot after a two-year interim gig that didn't just sail—hell, it soared. Memorial's...

Finzly Launches AI Security Layer Amid Rising Threats

Bank Security in the Age of AI You'd think banks, of all places, were impenetrable fortresses. But these days, they're more like digital targets. With AI-driven attacks becoming as common as morning coffee, Finzly's introducing Assure, an AI-powered security and assurance layer. It's about as timely as ever, given the 89% spike in AI-enabled attacks seen last year. When...

Perspecta's Study Reveals Troubling Data Accuracy Gaps

Data Accuracy in Healthcare: A Persistent Problem Just when you think data's about numbers and cold, hard facts, healthcare jolts you awake. Perspecta's fresh insights onto provider data accuracy aren't just a snooze fest of statistics but a genuine wake-up call. This report peels open a can of worms some might prefer to ignore. With only half of provider data accurate,...

Aesthetic M&A: Graper Harper's New Future Unfolds

Charlotte's Premier Practice Takes a Strategic Leap Graper Harper Cosmetic Surgery's recent partnership with Aesthetic Partners might not be the headline grabbing Wall Street tale we've grown accustomed to, but it's certainly worth noting. When a practice like Graper Harper, recognized as a jewel in Charlotte's cosmetic landscape, teams up with a player like Aesthetic...